Compare TX & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TX | RDY |
|---|---|---|
| Founded | 1961 | 1984 |
| Country | Luxembourg | India |
| Employees | 33253 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 9.9B |
| IPO Year | 2006 | 2001 |
| Metric | TX | RDY |
|---|---|---|
| Price | $55.26 | $12.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $37.70 | $16.90 |
| AVG Volume (30 Days) | 689.2K | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.31% | 0.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.60 | $7.72 |
| Revenue Next Year | $6.66 | $3.50 |
| P/E Ratio | $20.15 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.11 | $11.36 |
| 52 Week High | $55.66 | $15.67 |
| Indicator | TX | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 70.11 | 44.06 |
| Support Level | $41.60 | $11.47 |
| Resistance Level | $55.66 | $12.58 |
| Average True Range (ATR) | 1.71 | 0.20 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 66.02 | 59.50 |
Ternium SA is a flat steel producer operating in Mexico, Brazil, Argentina, Colombia, the southern United States, and Central America. It produces finished and semi-finished steel products and iron ore, which are sold either directly to steel manufacturers and steel processors or end-users. The company operates in two segments: Steel and Mining. In its Steel segment, the company produces slabs, billets & round bars, hot-rolled coils & sheets, bars & stirrups, wire rods, steel pipes, and other products. The Mining segment sells iron ore as concentrates (fines) and pellets. The vast majority of its revenue comes from the Steel segment and geographically from Mexico.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.